

## Tyvaso - (0.6 mg/ml; Solution, Inhalation)

|                              |                                                                                                                                                                                                                                                                      |                             |                                |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------|
| <b>Generic Name</b>          | Treprostinil Sodium                                                                                                                                                                                                                                                  | <b>Innovator</b>            | United Therapeutic Corporation |
| <b>Dosage</b>                | 0.6 mg/ml; Solution, Inhalation                                                                                                                                                                                                                                      | <b>Branded US Sales</b>     | Less Than \$1000 mn            |
| <b>Probable FTF</b>          | Less Than 5                                                                                                                                                                                                                                                          | <b>Known Para IV Filers</b> | Less Than 5                    |
| <b>Other ANDA developers</b> | Less Than 5                                                                                                                                                                                                                                                          | <b>Tentative Approvals</b>  | None                           |
| <b>Final Approvals</b>       | None                                                                                                                                                                                                                                                                 | <b>Generic Launches</b>     | None                           |
| <b>Indication</b>            | Indicated to increase walk distance in patients with WHO Group I pulmonary arterial hypertension and NYHA Class III symptoms. The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. |                             |                                |
| <b>Complexities</b>          | Yes                                                                                                                                                                                                                                                                  |                             |                                |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.